(Q38885852)

7 September 2017

23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial (English)

1 reference

7 September 2017

0 references

0 references

0 references

1 reference

N French

1

0 references

author name string

J Nakiyingi

2

1 reference

7 September 2017

L M Carpenter

3

1 reference

7 September 2017

E Lugada

4

1 reference

7 September 2017

C Watera

5

1 reference

7 September 2017

K Moi

6

1 reference

7 September 2017

M Moore

7

1 reference

7 September 2017

D Antvelink

8

1 reference

7 September 2017

D Mulder

9

1 reference

7 September 2017

E N Janoff

10

1 reference

7 September 2017

J Whitworth

11

1 reference

7 September 2017

C F Gilks

12

1 reference

7 September 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

7 September 2017

1 reference

7 September 2017

355

1 reference

7 September 2017

9221

1 reference

7 September 2017

2106-2111

1 reference

Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya

7 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Pneumococcal and influenza vaccination levels among HIV-infected adolescents and adults receiving medical care in the United States. Adult and Adolescent Spectrum of HIV Disease Project Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Pneumococcal vaccination in HIV-1-infected adults in Uganda: humoral response and two vaccine failures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

The impact of HIV on Streptococcus pneumoniae bacteraemia in a South African population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Prophylaxis for HIV-associated infections in the developing world

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

HIV-1 incidence and HIV-1-associated mortality in a rural Ugandan population cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Algorithms for detecting antibodies to HIV-1: results from a rural Ugandan cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Bacterial pneumonia in adult populations with human immunodeficiency virus (HIV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Mechanisms of host defense against infection with Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Serotype distribution and prevalence of resistance to benzylpenicillin in three representative populations of Streptococcus pneumoniae isolates from the coast of Kenya.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2902377-1

7 January 2021

10.1016/S0140-6736(00)02377-1

Identifiers

DOI

1 reference

7 September 2017

1 reference